Metastatic Breast Cancer Treatment Drug: ABRAXANE for Injectable Suspension

ABRAXANE for Injectable Suspension
Text size

Black Box Warning

ABRAXANE for Injectable Suspension is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

 

Legal Information for the Use of ABRAXANE.com

Conditions of Use

Please read these Terms of Use and Privacy Policy carefully. By proceeding to access and use this site, you are agreeing to these terms.

All contents, including text and images, are the property of Abraxis BioScience, Inc. and/or its affiliates, and may not be downloaded, stored, reposted, modified, distributed or otherwise used except as provided herein without the express written permission of Abraxis. Abraxis reserves the right to change this site and/or the information on it at any time without notification.

Information Only

Abraxis provides the information and material on this website for general information only. This information is not intended for or as a substitute for advice, treatment or medical judgment. Abraxis does not provide, and is not intending to provide or providing advice, treatment or medical judgment. Please consult with your health care provider before using any product referenced or discussed on this site.

Use Only in and for the United States

The information on this website is intended for use only by patients, health care providers and others in and for the United States. Other countries may have laws, regulatory requirements, and medical practices that differ from those in the United States and may require references to different or additional information. Because laws, regulations, and medical practices applicable in the United States differ from those in other countries, information on this site may not be appropriate for use, and may not and should not be relied upon, outside the United States.

Copyright Notice

This site is produced by Abraxis. Abraxis hereby grants you permission to copy documents published by Abraxis on the world wide web for noncommercial use only, and only if any copy you make shall retain all copyright and other proprietary notices as on this site. Any other reproduction of any material or information on this site, or the site itself is strictly and expressly prohibited. Nothing contained herein shall confer or be construed as conferring any license or right under any patent, trademark or copyright of Abraxis, its affiliates or any third party.

No Warranty or Guarantee; Limitation

Abraxis cannot and does not guarantee the accuracy of such information. This site is provided strictly "AS IS, WHERE IS." ABRAXIS MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE WITH RESPECT TO INFORMATION CONTAINED ON THIS WEBSITE, AND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, CREATED BY LAW, CONTRACT OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE OR NONINFRINGEMENT. IN NO EVENT SHALL ABRAXIS BE LIABLE FOR ANY DAMAGES OF ANY KIND OR NATURE, INCLUDING, WITHOUT LIMITATION, DIRECT, INDIRECT, SPECIAL (INCLUDING LOSS OF PROFIT) CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING FROM, OR IN CONNECTION WITH, THIS WEBSITE AND/OR THE INFORMATION CONTAINED HEREIN.

Links to Other Sites

Strictly as a resource to visitors of this website, Abraxis provides links to other websites, certain of which lead to resources located on servers maintained by third parties over whom Abraxis has no control. Abraxis cannot guarantee, and make no representations as to information contained on any website to which a link or reference is provided.

Prohibited Transmissions

Certain areas of this website may enable you to submit e-mails, or otherwise provide information or feedback to Abraxis or its representatives. Abraxis does not endorse, and specifically disclaims, any responsibility or liability for any content in any such submission. You may not post, submit or transmit any unlawful, threatening, libelous, defamatory, obscene, indecent, inflammatory, pornographic or profane material or any material that could constitute or encourage conduct that would be considered a criminal offense, give rise to civil liability or otherwise violate any law. You are prohibited from posting, submitting or transmitting any information which (i) infringes or may infringe any right of another, including privacy or publicity, (ii) is protected by copyright, trademark or other proprietary right, unless with the express written permission of its owner, or (iii) contains a virus, bug, worm or other harmful content. You shall be solely liable for any damage resulting from any post, submission or transmission you make.

User Information

Any "personally identifiable information" in electronic communications to the Site is governed by this website's Privacy Policy. On the other hand, any communication or material you transmit to this site by electronic mail or otherwise, including any data, questions, comments, suggestions or the like is, and will be treated as, non-confidential and non-proprietary. You understand that anything you post, submit or transmit may be used by Abraxis or representatives or its affiliates for any purpose, including reproduction, disclosure, transmission, publication, broadcast, and posting. Furthermore, Abraxis is free to use, for any purpose whatsoever and without compensation to you, any ideas, concepts, know-how, processes, or techniques contained in any communication you send, including without limitation, developing, manufacturing, marketing, and selling products and service using such ideas, concepts, know-how, processes, or techniques.

 

 

Important Safety Information & Boxed Warning

You should receive ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) under the care of a doctor who is trained to use cancer drugs. Because you may have side effects from your treatment, you should get this medicine in a clinic or hospital with doctors, nurses, and pharmacists who are trained to give cancer drugs.

ABRAXANE therapy should not be given to patients with metastatic breast cancer who have low blood counts. Low blood counts, especially low white blood cell counts, may make you more likely to get an infection. In order to check for low blood counts your doctor may need to take some blood to test your blood counts.

Note: Abraxane is paclitaxel made with the human blood protein albumin. This makes it behave differently in the body than regular paclitaxel. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL DRUGS.

Important Safety Information

One of the more important side effects associated with chemotherapy is neutropenia, which is a decrease in the number of infection-fighting white blood cells (neutrophils). Normal levels range from approximately 1,500 cells/mm3 to 1,800 cells/mm3 (but vary according to several factors, such as age and race). If levels fall below 500 cells/mm3, your risk of developing an infection increases and treatment may be interrupted. To avoid the risk of serious infection and fever, your doctor will monitor your absolute neutrophil count (ANC) during therapy.

Women should avoid becoming pregnant while being treated with ABRAXANE. Tell your doctor if you are pregnant, if you become pregnant, or you plan to become pregnant while taking ABRAXANE. Discuss with your doctor how ABRAXANE may affect fertility. Nursing a baby while taking ABRAXANE is not recommended because the drug may be present in breast milk

The most important adverse events included lower white and red blood cell counts, infections, tingling and numbness, nausea, vomiting, diarrhea, muscle and joint aches, and mouth sores. Other adverse reactions included weakness, visual disturbances, fluid retention, hair loss, and liver and kidney dysfunction. Low platelet counts, allergic reactions (which in rare cases were severe), cardiovascular reactions, and injection site reactions were uncommon.

Sensory neuropathy (numbness, tingling, or burning in the hands and feet) can occur with ABRAXANE and other paclitaxel medications. Severe sensory neuropathy can improve with proper management, as prescribed by your doctor. You should tell your nurse or doctor if you experience numbness, tingling, or burning in your hands or feet while taking ABRAXANE.

Please talk to your doctor or nurse if you have questions regarding the potential side effects of ABRAXANE therapy. You may want to review the Product Information, including Warnings, Precautions, and Contraindications.

The information on this site is intended for US residents only.

©2008 Abraxis BioScience, Inc.
and AstraZeneca Pharmaceuticals LP.
All Rights Reserved. AO 711/256325  2/08

ABRAXANE is marketed under a
co-promotion agreement between
Abraxis BioScience, Inc. and AstraZeneca.

Abraxis
AstraZeneca

Abraxis Oncology is a division of Abraxis
BioScience, Inc. All Abraxis BioScience,
Inc. corporate names, names of services,
and names of products referred to herein
are trade names, service marks, and/or
trademarks that are owned by or licensed
to Abraxis BioScience, its divisions or its
affiliates, unless otherwise noted.

Important Safety Information & Boxed Warning

You should receive ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) under the care of a doctor who is trained to use cancer drugs. Because you may have side effects from your treatment, you should get this medicine in a clinic or hospital with doctors, nurses, and pharmacists who are trained to give cancer drugs.

ABRAXANE therapy should not be given to patients with metastatic breast cancer who have low blood counts. Low blood counts, especially low white blood cell counts, may make you more likely to get an infection. In order to check for low blood counts your doctor may need to take some blood to test your blood counts.

Note: Abraxane is paclitaxel made with the human blood protein albumin. This makes it behave differently in the body than regular paclitaxel. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL DRUGS.

Important Safety Information

One of the more important side effects associated with chemotherapy is neutropenia, which is a decrease in the number of infection-fighting white blood cells (neutrophils). Normal levels range from approximately 1,500 cells/mm3 to 1,800 cells/mm3 (but vary according to several factors, such as age and race). If levels fall below 500 cells/mm3, your risk of developing an infection increases and treatment may be interrupted. To avoid the risk of serious infection and fever, your doctor will monitor your absolute neutrophil count (ANC) during therapy.

Women should avoid becoming pregnant while being treated with ABRAXANE. Tell your doctor if you are pregnant, if you become pregnant, or you plan to become pregnant while taking ABRAXANE. Discuss with your doctor how ABRAXANE may affect fertility. Nursing a baby while taking ABRAXANE is not recommended because the drug may be present in breast milk

The most important adverse events included lower white and red blood cell counts, infections, tingling and numbness, nausea, vomiting, diarrhea, muscle and joint aches, and mouth sores. Other adverse reactions included weakness, visual disturbances, fluid retention, hair loss, and liver and kidney dysfunction. Low platelet counts, allergic reactions (which in rare cases were severe), cardiovascular reactions, and injection site reactions were uncommon.

Sensory neuropathy (numbness, tingling, or burning in the hands and feet) can occur with ABRAXANE and other paclitaxel medications. Severe sensory neuropathy can improve with proper management, as prescribed by your doctor. You should tell your nurse or doctor if you experience numbness, tingling, or burning in your hands or feet while taking ABRAXANE.

Please talk to your doctor or nurse if you have questions regarding the potential side effects of ABRAXANE therapy. You may want to review the Product Information, including Warnings, Precautions, and Contraindications.

The information on this site is intended for US residents only.

©2008 Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP. All Rights Reserved. AO 711/256325  2/08
(Site updated 2/07)

ABRAXANE is marketed under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca.

Abraxis
AstraZeneca

Abraxis Oncology is a division of Abraxis BioScience, Inc. All Abraxis BioScience, Inc. corporate names, names of services, and names of products referred to herein are trade names, service marks, and/or trademarks that are owned by or licensed to Abraxis BioScience, its divisions or its affiliates, unless otherwise noted.